Results 201 to 210 of about 34,322 (240)

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. [PDF]

Cureus
Abdullah A, Polus L.
europepmc   +1 more source

Pharmacological Strategies for Preventing Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. [PDF]

Medicina (Kaunas)
Chen W, Tong X, Liu Y, Zhang X, Zhu S, Zhou Y, Wu Y, Zong Y.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Adalimumab

American Journal of Clinical Dermatology, 2009
Adalimumab is a recombinant, human, IgG1 monoclonal antibody specific for tumor necrosis factor. The clinical efficacy and safety of adalimumab (40 mg administered subcutaneously every other week) in patients with moderate-to-severe chronic plaque psoriasis have been demonstrated in several randomized, double-blind clinical trials, including the ...
Katherine F, Croom, Paul L, McCormack
openaire   +3 more sources

Adalimumab

BioDrugs, 2007
Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that ...
Greg L, Plosker, Katherine A, Lyseng-Williamson   +1 more
openaire   +3 more sources

Adalimumab

Reactions Weekly, 2021
  +5 more sources

Adalimumab

Annales de Dermatologie et de Vénéréologie, 2011
F, Aubin, H, Barthelemy
openaire   +3 more sources

Adalimumab

Nature Reviews Drug Discovery, 2003
Bornadata, Bain, Melanie, Brazil
openaire   +2 more sources

Adalimumab

Reactions Weekly, 2022
openaire   +2 more sources

HUMIRA (adalimumab)

SKINmed: Dermatology for the Clinician, 2004
William, Abramovits, Aditya K, Gupta
openaire   +2 more sources